Michael Nielsen says it's "very, very difficult for even the best scientists to accurately assess the value of scientific discoveries," which partly explains why some of the most influential revelations — like Einstein's theory of gravity — "were initially underappreciated." Despite their participation in a discipline so deeply vested in metrics and statistical significance, scientists have not yet determined the best way to judge the value of research, Nielsen says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.